The invention discloses an in-vitro expansion method for NK (Natural Killer) cells. The in-vitro expansion method comprises the following steps: (1) preparing a
reagent A which comprises main components of a 50 ng / ml anti-CD3
monoclonal antibody and a 50 ng / ml anti-CD16
monoclonal antibody, a
reagent B which comprises a main component of 300 IU / ml IL-2, and a
reagent C which comprises main components of 20 ng / ml IL-12 and 20 ng / ml IL-15, and preparing 40 ml of a
lymphocyte separation liquid as a reagent D; (2) enveloping the reagent A in a T-175 culture flask, and leaving to stand overnight at 4 DEG C; (3) treating
peripheral blood so as to obtain cells and serum; (4) suspending the cells, adding the reagent D, performing centrifugal collection on PBMC (
Peripheral Blood Mononuclear
Cell); (5) suspending the PBMC in an X-VIVO15 culture medium, adding the reagent B, the reagent C and
autologous serum, and performing incubation; (6) replenishing the culture medium, the reagent B, the reagent C and the
autologous serum on a third day, a sixth day, a ninth day and a twelfth day respectively, and collecting cells on a fourteenth day. The in-vitro expansion method has the beneficial effects that as the anti-CD3
monoclonal antibody and the anti-CD16
monoclonal antibody are inoculated in advance, and the cells are screened firstly, the expansion times and the purity of the NK cells in in-vitro culture are improved.